MXPA05001836A - Modulacion de polaridad opuesta de la expresion del nav.13. - Google Patents
Modulacion de polaridad opuesta de la expresion del nav.13.Info
- Publication number
- MXPA05001836A MXPA05001836A MXPA05001836A MXPA05001836A MXPA05001836A MX PA05001836 A MXPA05001836 A MX PA05001836A MX PA05001836 A MXPA05001836 A MX PA05001836A MX PA05001836 A MXPA05001836 A MX PA05001836A MX PA05001836 A MXPA05001836 A MX PA05001836A
- Authority
- MX
- Mexico
- Prior art keywords
- seq
- opposite polarity
- kcal
- mol
- oligo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Pain & Pain Management (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40341602P | 2002-08-14 | 2002-08-14 | |
PCT/US2003/025465 WO2004016754A2 (fr) | 2002-08-14 | 2003-08-14 | Modulation antisens de l'expression de nav1.3 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA05001836A true MXPA05001836A (es) | 2005-04-19 |
Family
ID=31888234
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA05001836A MXPA05001836A (es) | 2002-08-14 | 2003-08-14 | Modulacion de polaridad opuesta de la expresion del nav.13. |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1578927A2 (fr) |
JP (1) | JP2006507808A (fr) |
AU (1) | AU2003268096A1 (fr) |
BR (1) | BR0313455A (fr) |
CA (1) | CA2495398A1 (fr) |
MX (1) | MXPA05001836A (fr) |
WO (1) | WO2004016754A2 (fr) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1687410A4 (fr) | 2003-10-07 | 2008-04-09 | Isis Pharmaceuticals Inc | Oligonucleotides antisens optimises pour cibler le rein |
US20050191653A1 (en) | 2003-11-03 | 2005-09-01 | Freier Susan M. | Modulation of SGLT2 expression |
GB0719367D0 (en) | 2007-10-03 | 2007-11-14 | Procarta Biosystems Ltd | Transcription factor decoys, compositions and methods |
US9029337B2 (en) * | 2007-11-09 | 2015-05-12 | Isis Pharmaceuticals, Inc. | Modulation of factor 7 expression |
CN101984759A (zh) * | 2007-11-09 | 2011-03-09 | Isis药物公司 | 因子9表达的调节 |
GB0906130D0 (en) * | 2008-10-03 | 2009-05-20 | Procrata Biosystems Ltd | Transcription factor decoys |
CA2782375C (fr) * | 2009-12-23 | 2023-10-31 | Opko Curna, Llc | Traitement de maladies associees a la proteine ucp2 (uncoupling protein) par inhibition du produit de transcription antisens naturel en ucp2 |
GB201002413D0 (en) | 2010-02-12 | 2010-03-31 | Procarta Biosystems Ltd | Nucleic acid complexes |
GB201005545D0 (en) | 2010-04-01 | 2010-05-19 | Procarta Biosystems Ltd | Transcription factor decoys |
PL2585596T3 (pl) | 2010-06-23 | 2021-06-28 | Curna, Inc. | Leczenie chorób związanych z podjednostką alfa kanału sodowego bramkowanego napięciem (SCNA) poprzez hamowanie naturalnego transkryptu antysensownego SCNA |
PL3461895T3 (pl) | 2012-06-25 | 2021-01-11 | Ionis Pharmaceuticals, Inc. | Modulacja ekspresji ube3a-ats |
EP2931893A1 (fr) * | 2012-12-13 | 2015-10-21 | Universität Leipzig | Modulation des lymphocytes t par saut d'exon |
WO2016086104A1 (fr) | 2014-11-25 | 2016-06-02 | Ionis Pharmaceuticals, Inc. | Modulation de l'expression du ube3a-ats |
CA3004799C (fr) | 2015-11-12 | 2024-05-14 | F. Hoffmann-La Roche Ag | Oligonucleotides pour induire l'expression paternelle d'ube3a |
TWI809004B (zh) * | 2017-11-09 | 2023-07-21 | 美商Ionis製藥公司 | 用於降低snca表現之化合物及方法 |
US11939582B2 (en) * | 2018-08-20 | 2024-03-26 | Rogcon, Inc. | Antisense oligonucleotides targeting SCN2A for the treatment of SCN1A encephalopathies |
EP3947684A4 (fr) | 2019-03-29 | 2023-09-20 | Ionis Pharmaceuticals, Inc. | Composés et méthodes de modulation de ube3a-ats |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6610539B1 (en) * | 1997-07-10 | 2003-08-26 | Genesense Technologies, Inc. | Antisense oligonucleotide sequences as inhibitors of microorganisms |
US6124133A (en) * | 1999-10-15 | 2000-09-26 | Isis Pharmaceuticals Inc. | Antisense inhibition of fra-1 expression |
DE60230641D1 (de) * | 2001-09-14 | 2009-02-12 | Oxford Biomedica Ltd | Lentivirale vektoren zur behandlung von schmerzen |
-
2003
- 2003-08-14 CA CA002495398A patent/CA2495398A1/fr not_active Abandoned
- 2003-08-14 BR BRPI0313455-5A patent/BR0313455A/pt not_active Application Discontinuation
- 2003-08-14 EP EP03749047A patent/EP1578927A2/fr not_active Withdrawn
- 2003-08-14 WO PCT/US2003/025465 patent/WO2004016754A2/fr not_active Application Discontinuation
- 2003-08-14 JP JP2004529403A patent/JP2006507808A/ja not_active Withdrawn
- 2003-08-14 AU AU2003268096A patent/AU2003268096A1/en not_active Abandoned
- 2003-08-14 MX MXPA05001836A patent/MXPA05001836A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2495398A1 (fr) | 2004-02-26 |
BR0313455A (pt) | 2007-07-31 |
WO2004016754A3 (fr) | 2005-11-10 |
AU2003268096A8 (en) | 2004-03-03 |
AU2003268096A1 (en) | 2004-03-03 |
EP1578927A2 (fr) | 2005-09-28 |
WO2004016754A2 (fr) | 2004-02-26 |
JP2006507808A (ja) | 2006-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2546360T3 (es) | Modulación antisentido de la expresión de la apolipoproteína B | |
US6365354B1 (en) | Antisense modulation of lysophospholipase I expression | |
JP5501202B2 (ja) | C反応性タンパク質発現のアンチセンス調節 | |
JP4397585B2 (ja) | クラスタリン発現のアンチセンスモジュレーション | |
ES2307583T3 (es) | Inhibicion antisentido de expresion ptpib. | |
US6287860B1 (en) | Antisense inhibition of MEKK2 expression | |
JP2003503048A (ja) | Ship−2発現のアンチセンスモジュレーション | |
JP2003503371A (ja) | PI3Kp85発現のアンチセンス調節 | |
JP2004509619A (ja) | Flip−c発現のアンチセンスモジュレーション | |
JP2005520489A (ja) | アポリポタンパク質(a)発現のアンチセンス調節 | |
MXPA05001836A (es) | Modulacion de polaridad opuesta de la expresion del nav.13. | |
JP2003520042A (ja) | 誘導性一酸化窒素シンターゼ発現のアンチセンスモジュレーション | |
US20030092654A1 (en) | Antisense modulation of Inhibitor-kappa B Kinase-alpha expression | |
US6379960B1 (en) | Antisense modulation of damage-specific DNA binding protein 2, p48 expression | |
JP2003512070A (ja) | インテグリン−結合キナーゼ発現のアンチセンスモジュレーション | |
US6346416B1 (en) | Antisense inhibition of HPK/GCK-like kinase expression | |
JP2003505026A (ja) | 肝臓グリコーゲンホスホリラーゼ発現のアンチセンスモジュレーション | |
JP2003531630A (ja) | Dna結合阻害剤−1発現のアンチセンスモジュレーション | |
AU2001229537B2 (en) | Antisense modulation of macrophage migration inhibitory factor expression | |
JP2004503232A (ja) | C/EBPβ発現のアンチセンスモジュレーション | |
JP2003512079A (ja) | タンパク質キナーゼc−シータ発現のアンチセンスモジュレーション | |
JP2002531469A (ja) | アポトーシス−1の細胞性阻害物質の発現のアンチセンスモジュレーション | |
JP2005525829A (ja) | 糖質コルチコイド受容体発現のアンチセンス調節 | |
US6395544B1 (en) | Antisense modulation of BCAS1 expression | |
JP2003512037A (ja) | Bcl−6発現のアンチセンスモジュレーション |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |